hyPBase

SKU:BHN20152547
Catalog / Quick links
    Overview
    Click light‑blue chips for details
    GenCefe hyPBase mRNA for gene editing and genome engineering applications. Synthesised with Cap1(m7GpppNm) and 100% N1-methylpseudouridine (m1Ψ) substitution for reduced immunogenicity and improved translational efficiency. Supplied lyophilised, non-encapsulated; reconstitute in DEPC-treated water.
    Target hyPBase
    Application Gene Editing
    Modified Nucleotides N1-Me-Pseudo UTP
    5’ Cap Cap1 (m7GpppNm)
    Poly(A) Tail 100–120 nt
    Form Lyophilised Powder
    Species Human
    Grade RUO
    Available Options

    Select the variant that best fits your experiment. Availability and lead time may vary by option.

    • Size (6): 20 ug, 100 ug, 200 ug, 500 ug, 1 mg, 5 mg
    • Lead time: typically 3–4 weeks; timing may vary by selected option.
    • Storage: -80C
    • Shipping: cold-chain shipment (typically with ice packs).
    • Upon receipt: store at the recommended temperature (−80 °C) as soon as possible; avoid repeated freeze–thaw cycles.
    • Sales terms and conditions: Please review prior to ordering.
    Options selector
    Catalog no. Size
    IR0102002 20 ug
    IR0102010 100 ug
    IR0102020 200 ug
    IR0102050 500 ug
    IR0102100 1 mg
    IR0102500 5 mg
    Field Specification
    Concentration Provided as lyophilized powder. Add DEPC-treated water as needed.
    Formulation Non encapsulate
    Product Type
    • DNA&RNA
    • RNA
    • mRNA
    Shipping Lyophilized Powder
    Species Human
    Storage -80C
    Target hyPBase

    Overview

    This GenCefe mRNA encodes hyPBase, a transposase construct supplied for gene editing and genome engineering applications. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.

    mRNA Construct Design

    • 5′ Cap: Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1/IFIT3).
    • Modified Nucleotides: 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.
    • Poly(A) Tail: 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.
    • 5′ UTR: hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.
    • 3′ UTR: hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.
    • Signal Peptide: No
    • Protein Tag: No
    • Codon Optimisation: No (native human codon usage retained)
    • mRNA Length: Provided upon order placement.
    • Form: Lyophilised powder; reconstitute in DEPC-treated water as needed.

    This mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.

    Biological Background

    Transposases are enzymes that catalyse the cut-and-paste (Class II) or copy-and-paste transposition of discrete DNA elements (transposons) into host genomes in a sequence-specific manner. Hyperactive Sleeping Beauty transposase (hyPBase) and Sleeping Beauty 100x (SB100X) are engineered variants of the Salmo salar Tc1/mariner-family transposon system with substantially enhanced integration activity relative to the wild-type enzyme. Co-delivery of transposase mRNA with a donor plasmid carrying the transposon cargo offers a non-viral route to stable genomic integration, commonly employed in CAR T-cell manufacturing, gene therapy research, and stable cell line generation where viral vector capacity or safety restrictions limit alternative approaches.

    Research Relevance and Current Trends

    • Non-viral CAR T manufacturing: Sleeping Beauty transposon systems with hyperactive transposase mRNA are in clinical-stage evaluation for cost-effective, GMP-compatible stable CAR integration into T cells.
    • Stable reporter cell generation: Transposase mRNA + transposon plasmid co-delivery generates stable fluorescent or selection-marked cell lines without lentiviral handling constraints.
    • High-throughput genetic screen libraries: piggyBac (hyPBase) systems enable reversible, scarless transgene removal after selection due to transposon excision, supporting iterative genetic library strategies.

    Common Research Applications

    • Stable transgene integration — co-delivery of transposase mRNA with transposon donor plasmid for non-viral genomic integration of therapeutic or reporter constructs.
    • CAR T-cell manufacturing research — SB100X or hyPBase transposase mRNA in T-cell engineering studies for stable CAR expression without lentiviral production.
    • Selection cassette integration — stable antibiotic resistance marker insertion followed by transposase-mediated excision for scarless genetic modification.

    Notes for Experimental Interpretation

    • Transposase mRNA activity requires co-delivery of a compatible transposon plasmid carrying ITR sequences flanking the cargo; confirm ITR compatibility with the specific transposase variant used (SB- or piggyBac-specific ITRs are not interchangeable).
    • Integration site distribution is semi-random for both SB and hyPBase systems; for applications requiring site-specific integration, confirm acceptable genomic safety profiles by integration site analysis.
    • Stable cell selection (antibiotic or FACS) should begin 48–72 h post-transfection; delayed selection may reduce clonal yield from incomplete transposition events.

    Synthetic mRNA products typically incorporate chemical modifications to minimize innate immune recognition. The most widely used modification is N1-methylpseudouridine (m1Ψ) substitution at all uridine positions, which reduces activation of Toll-like receptors (TLR7/TLR8) and protein kinase R (PKR), resulting in improved translational efficiency and a reduced inflammatory response. The 5′ cap structure is equally important: Cap1 (m7GpppNm), which includes 2′-O-methylation at the first transcribed nucleotide, closely mimics endogenous mammalian mRNA and limits recognition by innate immune sensors such as IFIT1 and IFIT3. Together, these modifications support more robust and sustained protein expression in research applications.

    Synthetic mRNA is highly sensitive to ribonuclease (RNase) degradation and must be handled carefully. Lyophilized products should be stored at −20°C; aqueous formulations should be kept at −70°C or below. Repeated freeze-thaw cycles should be avoided — aliquoting immediately upon receipt is strongly recommended. All handling must be performed in an RNase-free environment using dedicated pipettes, nuclease-free consumables, and DEPC-treated or certified nuclease-free water. RNA integrity should be confirmed by agarose gel electrophoresis or capillary electrophoresis (e.g., Bioanalyzer or Fragment Analyzer) before use in critical experiments, particularly for transfection or in vivo delivery applications.

    Linear mRNA and circular RNA (circRNA) differ fundamentally in structure, stability, and translational mechanism. Linear mRNA carries a 5′ cap and poly(A) tail that enable efficient cap-dependent translation by the ribosome; it is ideal for studies requiring rapid, high-level transient protein expression, mRNA delivery research, and immunogen modeling. circRNA lacks free 5′ and 3′ ends, making it inherently resistant to exonucleolytic degradation, which confers substantially greater intracellular stability. Translation of circRNA occurs via internal ribosome entry sites (IRES) or other cap-independent mechanisms. circRNA is particularly valuable for miRNA sponge applications, sustained transgene expression platforms, and studies of RNA stability and function. Choose linear mRNA when fast, high-yield transient expression is needed; choose circRNA when extended intracellular stability, prolonged expression, or sponge-based loss-of-function studies are the priority.

    Quality-controlled synthetic mRNA should be characterized by multiple orthogonal analytical methods. Standard assessments include: agarose gel electrophoresis or capillary electrophoresis (Bioanalyzer, Fragment Analyzer) to confirm full-length transcript integrity; HPLC to assess purity and residual double-stranded RNA (dsRNA) content; UV spectrophotometry for concentration and A260/A280 ratio; and optionally LC-MS for sequence and modification verification. A Certificate of Analysis (CoA) should accompany each lot, documenting yield, purity, integrity score, and endotoxin level (LAL assay) for products used in cell-based or animal studies. Functional activity is further confirmed by in vitro transfection followed by protein detection (e.g., flow cytometry, Western blot, or luminescence assay), confirming translational competence of the final product.

    Synthetic mRNA can be delivered into cells and organisms through several established modalities. For in vitro applications, lipid-based transfection reagents (lipofection), electroporation, and polymer-based nanoparticles are the most common approaches. Lipid nanoparticles (LNPs) are the gold-standard delivery system and support high transfection efficiency both in vitro and in vivo. For in vivo studies, intramuscular, intravenous, intratumoral, or intraperitoneal administration may be used depending on the target tissue and research objective; the choice of delivery vehicle (LNP, polymeric carrier, or direct injection) should be matched to the organ of interest and application. Delivery efficiency is influenced by mRNA modifications, concentration, formulation composition, and cell type; optimization experiments are recommended for each new experimental system before scaling.

    Can't find the mRNA or circRNA construct you need? We offer custom synthesis and add-on services to help you move your project forward — from sequence design and codon optimization to custom mRNA synthesis and circular RNA (circRNA) production for both in vitro and in vivo applications. Options may include chemically modified mRNA (e.g., N1-methylpseudouridine substitution, Cap1 capping strategy), circRNA synthesis via chemical ligation (short segments ≤100 nt) or IVT-based cyclization (longer constructs ≥200 nt), HPLC purification, and full QC documentation including gel or Bioanalyzer integrity analysis and a Certificate of Analysis. Additional options may include multiple synthesis scales from small research batches to larger quantities, miRNA sponge circRNA constructs, IRES element selection for cap-independent circRNA translation, labels and conjugation, and delivery formulation guidance. We can also assist with negative and scramble control formats and related RNA tools when a catalog product does not meet your specifications. Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.

    Get a Quote

    Please use this form for bulk quantity requests or customized products.

    Contact Information

    Product Information

    Try Celltrypse Free – Request Your Sample Today

    Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.